New scope 3 target: 33% reduction by 2033 (2024 baseline) Novo Nordisk set a new SBTi-aligned target to reduce absolute scope 3 emissions by 33% by 2033, using 2024 as baseline. Target covers nearly 70% of scope 3 emissions and submitted to SBTi for validation. Consistent with SBTi well-below 2.0°C pathway.
▾ expand
30% plastic footprint reduction per patient by 2033 Set global target to reduce plastic per patient by 30% by 2033 vs 2024 baseline of 0.35 kg/patient. Includes transition to reusable devices and circular product design.
▾ expand
Nature roadmap: halt nature loss by 2033, nature-positive by 2045 Formalised nature roadmap to halt loss of nature in value chain by 2033, and become nature positive by 2045. Includes water withdrawal savings, deforestation-free supply chain ambitions, biodiversity restoration.
▾ expand
Acquired three Catalent fill-finish sites for USD 11.7 billion On 18 December 2024, Novo Nordisk acquired three fill-finish sites located in US (Bloomington), Italy (Anagni) and Belgium (Brussels) from Novo Holdings A/S, in connection with Novo Holdings' acquisition of Catalent Inc. About 3,500 employees included. Total cash consideration USD 11.7bn (DKK 82.1bn).
▾ expand
Restated scope 3 methodology (cats 1, 2, 4, 6) Updated scope 3 methodology for purchased goods, capital goods, upstream transport and business travel. Cat 1 restated from 2,067 to 1,018 ktCO2e; Cat 2 from 1,315 to 303 ktCO2e in 2023. Previously overstated due to spend-based factor uncertainty. Total 2023 scope 3 restated from 1,836 to 1,743 ktCO2e.
▾ expand
Lost-time accident frequency calculation harmonised to international standard Changed from 1,600 to 2,000 working hours per FTE per year for accident rate calculation, in line with international standard. Comparatives restated.
▾ expand
First Sustainability Statement under CSRD with double materiality assessment 2024 is first Sustainability statement prepared under EU CSRD requirements, including double materiality assessment identifying patient protection, climate change, resource use and circular economy, and own workforce as essential topics.
▾ expand
Scope 3 baseline reset to 2024 for new 2033 target Updated scope 3 decarbonisation roadmap with 2024 as new baseline (1,493 ktCO2e for target scope). Previously baseline was 2019. Target covers ~70% of scope 3 in line with SBTi provisions.
▾ expand
Updated scope 3 decarbonisation roadmap expanding scope Updated scope 3 roadmap expanded from operations and transportation to cover operations and value chain globally. With projected growth, anticipate overall growth in GHG emissions until 2030 before decline.
▾ expand
Carbon removals to neutralise residual emissions beyond 2033 Beyond 2033, Novo Nordisk expects to use carbon removals to neutralise residual CO2e emissions of up to 10% of baseline emissions toward net zero 2045, in line with SBTi requirements and IPCC guidance. Exploring opportunities involving both nature-based and technology-based solutions. Estimates residual emissions after decarbonisation levers to be 150 thousand tonnes CO2e. Does not currently use biodiversity offsets as part of nature roadmap.
▾ expand
see 6 more events →